NCT04611022 Educate and Improve Underserved Populations' Uptake and Completion of the HPV Vaccine
| NCT ID | NCT04611022 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Colorado, Denver |
| Condition | Human Papilloma Virus |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2020-08-28 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,000 participants in total. It began in 2020-08-28 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The educational intervention to be delivered by the PN(Patient Navigator) consists of "toolkit education materials" developed by the National Cancer Institute (NCI) and a small media intervention (i.e., video) that our research team has developed. The NCI-produced toolkit education materials consist of Power Point presentations, flyers, and posters that contain information about HPV(Human Papilloma Virus), HPV-related cancers, and the importance of the HPV vaccine series for adolescents (9-17 years old) and young adults (18-26 year old) who are eligible for the vaccine.
Eligibility Criteria
Inclusion Criteria: 1. Be a Denver Health patient\* 18-26 years old, who has not started or completed the HPV vaccine series (Vaccine completion for this age group is 3 doses). 2. Be a parent of a Denver Health adolescent patient\* aged 9-17 years old, who has not started or completed the HPV vaccine series. (Vaccine completion is 2 doses for 9-14-year-old, and 3 doses for 14-17-year old) 3. English and/or Spanish Speaking 4. Stated willingness to comply with all study procedures and be available for the duration of the study * Denver Health patients will be identified from one of the following clinics; Denver Health Clinics Eastside Adult Clinic, Eastside Women's Care Clinic, Westside Adult Clinic, Westside Women's Care Clinic, Pavilion C: Women's Care Clinic, La Casa-Quigg Newton Family Health Center, Lowry Family Health Center, Montbello Family Health Center, Westwood Family Health Center, Parkhill Family Health Center, Webb Center For Primary Care, Pena Southwest Clinic Exclusion Criteria: 1. Individuals who do not meet eligibility criteria, including individuals who do not speak English or Spanish \[at the discretion of the CHE or PN upon recruitment\] 2. Decisionally-challenged adults with cognitive or personality impairment or due to intoxication (alcohol or drugs) that might interfere with their ability to consent or participate in the study \[at the discretion of the CHE or PN upon recruitment\] 3. Individuals from vulnerable populations (e.g., inmates, homeless, pregnant women, and those with auditory impairment \[at the discretion of the CHE or PN upon recruitment\] 4. Individuals under the age of 18 years.
Contact & Investigator
Evelinn Borrayo
PRINCIPAL INVESTIGATOR
University of Colorado, Denver
Frequently Asked Questions
Who can join the NCT04611022 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Human Papilloma Virus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04611022 currently recruiting?
Yes, NCT04611022 is actively recruiting participants. Contact the research team at Sindy.Gonzalez@CUAnschutz.edu for enrollment information.
Where is the NCT04611022 trial being conducted?
This trial is being conducted at Denver, United States.
Who is sponsoring the NCT04611022 clinical trial?
NCT04611022 is sponsored by University of Colorado, Denver. The principal investigator is Evelinn Borrayo at University of Colorado, Denver. The trial plans to enroll 1,000 participants.